Metabolic dysfunction-associated fatty liver disease (MAFLD) has replaced Nonalcoholic Fatty Liver Disease (NAFLD) due to the inclusion of cardiometabolic criteria. MAFLD is defined by hepatic steatosis associated with metabolic alterations, including obesity, diabetes, and metabolic syndrome. Lifestyle modifications, such as proper nutrition and regular exercise, are the cornerstone of MAFLD treatment. Nutraceuticals like silymarin, berberine, curcumin, Nigella sativa, Ascophyllum nodosum, and Fucus vesiculosus, along with vitamin E and coenzyme Q10, have shown potential benefits in improving metabolic and hepatic conditions. However, more research is needed on their long-term efficacy and safety. Pharmacological therapies, including incretins and PCSK9 inhibitors, have shown promise in managing cardiometabolic risk factors associated with MAFLD. The review highlights the importance of tailored therapies for MAFLD patients, emphasizing the need for further studies to optimize nutraceutical and pharmacological treatments. Lifestyle changes, including a Mediterranean diet and high-intensity interval exercise, are recommended for managing MAFLD. The article also discusses the association between MAFLD and cardiovascular disease, highlighting the need for increased attention to MAFLD in the medical community. Overall, the review provides an overview of current therapeutic strategies for the treatment and prevention of MAFLD.Metabolic dysfunction-associated fatty liver disease (MAFLD) has replaced Nonalcoholic Fatty Liver Disease (NAFLD) due to the inclusion of cardiometabolic criteria. MAFLD is defined by hepatic steatosis associated with metabolic alterations, including obesity, diabetes, and metabolic syndrome. Lifestyle modifications, such as proper nutrition and regular exercise, are the cornerstone of MAFLD treatment. Nutraceuticals like silymarin, berberine, curcumin, Nigella sativa, Ascophyllum nodosum, and Fucus vesiculosus, along with vitamin E and coenzyme Q10, have shown potential benefits in improving metabolic and hepatic conditions. However, more research is needed on their long-term efficacy and safety. Pharmacological therapies, including incretins and PCSK9 inhibitors, have shown promise in managing cardiometabolic risk factors associated with MAFLD. The review highlights the importance of tailored therapies for MAFLD patients, emphasizing the need for further studies to optimize nutraceutical and pharmacological treatments. Lifestyle changes, including a Mediterranean diet and high-intensity interval exercise, are recommended for managing MAFLD. The article also discusses the association between MAFLD and cardiovascular disease, highlighting the need for increased attention to MAFLD in the medical community. Overall, the review provides an overview of current therapeutic strategies for the treatment and prevention of MAFLD.